NEOLEUKIN THERAPEUTICS INC's ticker is NLTX and the CUSIP is 64049K104. A total of 47 filers reported holding NEOLEUKIN THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $57,719 | +18.2% | 69,541 | -0.3% | 0.00% | – |
| Q1 2023 | $48,836 | +37.5% | 69,765 | 0.0% | 0.00% | – |
| Q4 2022 | $35,510 | -21.1% | 69,765 | 0.0% | 0.00% | – |
| Q3 2022 | $45,000 | -37.5% | 69,765 | -0.2% | 0.00% | – |
| Q2 2022 | $72,000 | -87.6% | 69,890 | -77.4% | 0.00% | – |
| Q1 2022 | $581,000 | -63.1% | 308,838 | -5.4% | 0.00% | – |
| Q4 2021 | $1,574,000 | -38.1% | 326,497 | -7.1% | 0.00% | – |
| Q3 2021 | $2,541,000 | -24.5% | 351,388 | -3.6% | 0.00% | -100.0% |
| Q2 2021 | $3,364,000 | -26.9% | 364,492 | -2.5% | 0.00% | 0.0% |
| Q1 2021 | $4,603,000 | -19.4% | 373,955 | -7.7% | 0.00% | 0.0% |
| Q4 2020 | $5,714,000 | +14.3% | 405,224 | -2.7% | 0.00% | 0.0% |
| Q3 2020 | $4,998,000 | +115.0% | 416,503 | +197.3% | 0.00% | 0.0% |
| Q2 2020 | $2,325,000 | +170.7% | 140,078 | +85.7% | 0.00% | – |
| Q1 2020 | $859,000 | +27.3% | 75,440 | +37.7% | 0.00% | – |
| Q4 2019 | $675,000 | +407.5% | 54,769 | +17.7% | 0.00% | – |
| Q3 2019 | $133,000 | – | 46,535 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 2,291,133 | $1,166,187 | 1.01% |
| Privium Fund Management (UK) Ltd | 117,200 | $59,655 | 0.04% |
| Redmile Group, LLC | 1,850,566 | $941,938 | 0.04% |
| Baker Brothers Advisors | 3,821,740 | $1,945,266 | 0.01% |
| Kynam Capital Management, LP | 120,764 | $61,469 | 0.01% |
| Sio Capital Management, LLC | 38,312 | $19,501 | 0.01% |
| SIMON QUICK ADVISORS, LLC | 46,856 | $23,850 | 0.00% |
| Tri Locum Partners LP | 10,248 | $5,000 | 0.00% |
| Endurance Wealth Management, Inc. | 20,000 | $10 | 0.00% |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 75,000 | $38,175 | 0.00% |